Piper Sandler Raises Edwards Lifesciences (NYSE:EW) Price Target to $88.00

Edwards Lifesciences (NYSE:EW) had its target price raised by Piper Sandler from $85.00 to $88.00 in a report published on Friday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

EW has been the subject of a number of other reports. Mizuho upped their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a buy rating in a research report on Thursday, April 11th. Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a hold rating in a research report on Wednesday, February 7th. OTR Global raised shares of Edwards Lifesciences from a mixed rating to a positive rating in a research report on Tuesday, March 26th. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an outperform rating in a research report on Monday, April 15th. Finally, Morgan Stanley increased their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an overweight rating in a research report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $92.71.

Edwards Lifesciences Stock Down 1.8 %

Shares of NYSE EW opened at $86.43 on Friday. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average price of $90.28 and a 200 day moving average price of $78.95. The company has a market cap of $52.02 billion, a P/E ratio of 37.25, a P/E/G ratio of 4.29 and a beta of 1.05. Edwards Lifesciences has a 12-month low of $60.57 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. Research analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last quarter. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in the company. Martin Capital Advisors LLP increased its stake in shares of Edwards Lifesciences by 0.5% during the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after acquiring an additional 128 shares during the period. Legacy Wealth Asset Management LLC grew its position in Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after buying an additional 134 shares during the last quarter. Chapin Davis Inc. grew its position in Edwards Lifesciences by 1.7% in the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after buying an additional 140 shares during the last quarter. Johnson Financial Group Inc. grew its position in Edwards Lifesciences by 23.0% in the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after buying an additional 144 shares during the last quarter. Finally, Valley National Advisers Inc. grew its position in Edwards Lifesciences by 6.0% in the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after buying an additional 152 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.